X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VENT-03 is a first-in-class, orally administered cGAS inhibitor. it is under phase 1 clinical development for the treatment of systemic lupus erythematosus (SLE) and other inflammatory disorders.
Lead Product(s): VENT-03
Therapeutic Area: Immunology Product Name: VENT-03
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
VENT-02, a novel, orally administered, brain-penetrant NLRP3 inhibitor, is being investigated in neuroinflammatory diseases, including Parkinson’s, Alzheimer’s, and refractory epilepsy, as well as systemic diseases.
Lead Product(s): VENT-02
Therapeutic Area: Neurology Product Name: VENT-02
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2023
Details:
Ventus will use the grant to support the identification and development of a NLRP3 PET tracer derived from its portfolio of selective brain-penetrant NLRP3 inhibitors, including VENT-02.
Lead Product(s): VENT-02
Therapeutic Area: Neurology Product Name: VENT-02
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: MJFF
Deal Size: $0.1 million Upfront Cash: Undisclosed
Deal Type: Funding April 20, 2023
Details:
VENT-01, Ventus’ lead drug programme, is a peripherally restricted small molecule inhibitor compound that acts on NLR pyrin domain-containing 3 (NLRP3).
Lead Product(s): VENT-03
Therapeutic Area: Immunology Product Name: VENT-03
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
VENT-02 has demonstrated potent inhibition of NLRP3 activity in peripheral blood mononuclear cells and whole blood across species. VENT-02 also showed an excellent CNS-to-plasma exposure ratio in all preclinical species.
Lead Product(s): VENT-02
Therapeutic Area: Neurology Product Name: VENT-02
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
VENT-01, Ventus’ first lead program is a peripherally restricted small molecule inhibitor compound targeting NLRP3 for the treatment of renal cardiovascualr hepatic disease.
Lead Product(s): VENT-01
Therapeutic Area: Nephrology Product Name: VENT-01
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
Under the agreement, Novo Nordisk will receive worldwide rights to develop and commercialize Ventus’ lead NLRP3 inhibitor program VENT-01, for a broad range of diseases, including nonalcoholic steatohepatitis, chronic kidney disease, and other cardiometabolic conditions.
Lead Product(s): VENT-01
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VENT-01
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $703.0 million Upfront Cash: $70.0 million
Deal Type: Licensing Agreement September 29, 2022
Details:
Proceeds will accelerate the scale-up of ReSOLVETM platform to address targets previously considered undruggable and advance the company’s small molecule pipeline across a broad range of diseases, including VENT-01.
Lead Product(s): VENT-01
Therapeutic Area: Immunology Product Name: VENT-01
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: SoftBank Vision Fund 2
Deal Size: $140.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing February 09, 2022
Details:
VENT-01, Ventus first lead program, a peripherally restricted small molecule inhibitors for neurological indications associated with NLRP3 activation, such as Parkinson’s disease, traumatic brain injury and Alzheimer’s disease.
Lead Product(s): VENT-01
Therapeutic Area: Immunology Product Name: VENT-01
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2021
Details:
Proceeds from the Series B will be used to advance Ventus’ pipeline of novel medicines to treat diseases in multiple therapeutic areas and expand platform capabilities.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: BVF Partners L.P
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
